In addition, researchers utilising a KrasG12D-driven lung cancer murine model with genetic deficiency for IL-6 reported that the presence of oncogenic KRAS mutation leads to a reduction in tumour growth and improved survival23. This evidence concerns the gene KRAS and neoplasm.